US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD

25.91

+2.299.70%

Volume:1.39M

Turnover:35.48M

Market Cap:1.49B

PE:-11.13

High:26.25

Open:24.15

Low:24.11

Close:23.62

Loading ...

Overview Company News Filings

Is Structure Therapeutics Inc. (NASDAQ:GPCR) the Most Promising Small-Cap Stock According to Analysts?

LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study

JPMorgan says Lilly data ‘highly favorable’ for Structure Therapeutics

BUZZ-Eli Lilly jumps as pill leads to 7.9% weight loss in late-stage trial

Shares of Obesity Drug Developer Structure Therapeutics up 24.6% Premarket After Eli Lilly's Pill Leads to 7.9% Weight Loss in Late-Stage Trial

THOMSON REUTERS

NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback

Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill

Viking, Structure rally after Pfizer halts obesity drug development

Obesity Drugmakers Shares Rise After Pfizer Ends Development of Weight-Loss Pill Danuglipron

Press Release: Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results

Biotech stocks have been hit by 'DOGE' and other fears. Why they're a great value now.

Septerna, Inc. (SEPN): Among Top Insider Purchases Last Month

Analysts Have Conflicting Sentiments on These Healthcare Companies: Fate Therapeutics (FATE), Organon (OGN) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)

BUZZ-Jefferies looks to Lilly data to reignite interest in obesity stocks

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.

Morgan Stanley Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Structure Therapeutics Is Maintained at Market Outperform by Citizens Capital Markets

William Blair Initiates Structure Therapeutics at Outperform

MT Newswires Live

Structure Therapeutics Initiated at Outperform by William Blair

U.S. RESEARCH ROUNDUP-Autodesk, Coca-Cola, NetApp

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/GPCR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GPCR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GPCR\",,,,,undefined,":{"symbol":"GPCR","market":"US","secType":"STK","nameCN":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","latestPrice":25.91,"timestamp":1745956800000,"preClose":23.62,"halted":0,"volume":1391295,"delay":0,"floatShares":49653148,"shares":57342847,"eps":-2.327592,"marketStatus":"Pre-Mkt","change":2.29,"latestTime":"04-30 04:00:43 EDT","open":24.15,"high":26.25,"low":24.1067,"amount":35478380.062815,"amplitude":0.090741,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.327592,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1746019800000},"marketStatusCode":1,"adr":0,"adrRate":3,"listingDate":1675400400000,"exchange":"NASDAQ","adjPreClose":25.91,"postHourTrading":{"tag":"盘后","latestPrice":24.62,"preClose":25.91,"latestTime":"19:00 EDT","volume":8732,"amount":226000.46,"timestamp":1745967646596},"volumeRatio":1.659812889872901,"impliedVol":0.9105,"impliedVolPercentile":0.7711},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GPCR\",,,,,undefined,":{"symbol":"GPCR","floatShares":49653148,"roa":"-14.28%","roe":"-18.60%","lyrEps":-2.327592,"volumeRatio":1.659812889872901,"shares":57342847,"dividePrice":0,"high":26.25,"amplitude":0.090741,"preClose":23.62,"low":24.1067,"week52Low":13.22,"pbRate":"1.72","week52High":62.74,"institutionHeld":0,"latestPrice":25.91,"eps":-2.327592,"divideRate":0,"volume":1391295,"delay":0,"ttmEps":-2.327592,"open":24.15,"prevYearClose":27.12,"prevWeekClose":23.74,"prevMonthClose":17.31,"prevQuarterClose":17.31,"fiveDayClose":23.04,"twentyDayClose":17.31,"sixtyDayClose":29.97},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GPCR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530199527","title":"Is Structure Therapeutics Inc. (NASDAQ:GPCR) the Most Promising Small-Cap Stock According to Analysts?","url":"https://stock-news.laohu8.com/highlight/detail?id=2530199527","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530199527?lang=en_us&edition=fundamental","pubTime":"2025-04-26 04:31","pubTimestamp":1745613110,"startTime":"0","endTime":"0","summary":"We recently published a list of the 11 Most Promising Small-Cap Stocks According to Analysts. In this article, we are going to take a look at where Structure Therapeutics Inc.  stands against other promising small-cap stocks.Robert Teeter of Silvercrest Asset Management recently appeared in an interview to express that he thinks small-cap stocks are currently facing a choppy market, but he also acknowledged that he anticipates a rally later in the year. Based on this sentiment, he advised clients on the importance of diversification within the S&P 500 and pointed to opportunities in international markets. We covered his stance in greater detail in one of our other articles,10 Best Small-Cap Value Stocks to Buy Now. Here’s an excerpt from it:. Why are we interested in the stocks that hedge funds pile into?The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/structure-therapeutics-inc-nasdaq-gpcr-203150034.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SDS","SPY","BK4588","TSYW.SI","BK4112","BK4504","NQmain","GPCR","BK4599",".SPX","QID","SQQQ","NDAQ","BK4534","BK4007",".IXIC","NVIW.SI","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BKPKM429.USD","OEF","SPXU","QLD","SSO","USJW.SI","SH","MNQmain","VOO","ESmain","IE00B64PRP62.GBP","BK4559","IVV","BK4550","LU2210149790.SGD","LU2210150020.SGD","BK4581","TQQQ","USAW.SI","IE00BGHQF748.EUR","BK4585","OEX","PSQ"],"gpt_icon":1},{"id":"2529138887","title":"LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2529138887","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529138887?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:37","pubTimestamp":1745239020,"startTime":"0","endTime":"0","summary":"Shares of Eli Lilly LLY soared 14.3% on April 17 after data from a late-stage study showed that orforglipron achieved the primary goal of significantly reducing A1C levels compared to placebo at 40 weeks, with an average A1C reduction of 1.3% to 1.6% from a baseline of 8%. LLY’s orforglipron is an investigational, once-daily small-molecule oral GLP-1 receptor agonist that can be administered at any time of the day without restrictions on food and water intake.The phase III ACHIEVE-1 study, the first of sevenlate-stage studies, is evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes  and inadequate glycemic control with diet and exercise alone. The enrolled patients in the 40-week study were randomized equally to receive either a 3 mg, 12 mg or 36 mg dose of orforglipron or placebo. Lilly is also developing a version of this oral drug for obesity.Year to date, shares of Lilly have gained 8.8% against the industry’s 3.3% decline.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lly-stock-oral-glp-1-123700472.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2089984988.USD","LU0096364046.USD","LU1023059063.AUD","LU0256863811.USD","LU1366192091.USD","LU1720051108.HKD","LU1868836757.USD","LU0471298777.SGD","LU2361044949.HKD","LU1712237335.SGD","IE00B2B36J28.USD","LU2360106947.USD","LU0456855351.SGD","LU2324357040.USD","LU1093756168.USD","VKTX","LU1868837300.USD","NVO","LU1280957306.USD","IE00BZ1G4Q59.USD","BK4534","LU2237443465.HKD","LU2264538146.SGD","LU2237443622.USD","LU0417517546.SGD","LLY","LU0640476718.USD","LU0094547139.USD","LU1035775433.USD","LU1551013342.USD","LU2106854487.HKD","LU2471134952.CNY","LU0943347566.SGD","SG9999017495.SGD","LU2237443382.USD","IE00BK4W5L77.USD","GPCR","LU1061106388.HKD","LU0354030511.USD","LU0114720955.EUR","IE0004445239.USD","LU1548497426.USD","III","GLP","SG9999018865.SGD","BK4581","LU0238689110.USD","LU1093756325.SGD","BK4532","LU1720051017.SGD"],"gpt_icon":1},{"id":"2528060378","title":"JPMorgan says Lilly data ‘highly favorable’ for Structure Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2528060378","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528060378?lang=en_us&edition=fundamental","pubTime":"2025-04-18 22:26","pubTimestamp":1744986368,"startTime":"0","endTime":"0","summary":"JPMorgan analyst Hardik Parikh says Eli Lilly’s  Phase 3 data for orforglipron in type 2 diabetes suggest a “highly competitive profile” for the drug. The firm views the data as its base case scenario, whereby Structure Therapeutics  shares could be up double-digit percent in this scenario on a “highly favorable read-through” and Viking Therapeutics  could move mid-single-digit in either direction. JPMorgan’s focus was primarily on orfoglipron’s tolerability profile with the extended titration, and here the data is highlighted by an 8% discontinuation rate on the highest dose versus low-teens expectations, the analyst tells investors in a research note. The firm sees the data as “helping derisk the category,” giving more confidence that Structure can also bring tolerability of aleniglipron to reasonable levels. For Viking, the read-through is not as direct, and today’s data “clearly helps derisk a strong” first in class oral competitor from Lilly, which could limit the potential of lat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/jpmorgan-says-lilly-data-highly-142608655.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jpmorgan-says-lilly-data-highly-142608655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4550","LU1291159041.SGD","SG9999015952.SGD","IE00BJT1NW94.SGD","LU0256863811.USD","LU2237438978.USD","SGXZ57979304.SGD","LU1883839398.USD","LU0238689110.USD","BK4516","LU0234572021.USD","SG9999014880.SGD","LU1267930730.SGD","LU2552382215.SGD","IE00BLSP4239.USD","SG9999015945.SGD","LU0820561818.USD","SG9999001176.SGD","LU2357305700.SGD","LU0321505439.SGD","BK4585","GPCR","LU2602419157.SGD","LU0198837287.USD","LU0689472784.USD","LU2360106947.USD","LU2237443465.HKD","LU2237443622.USD","IE0009355771.USD","LU1232071149.USD","LU2023250504.SGD","SG9999001176.USD","SG9999002224.SGD","LU2237443895.HKD","LU1720051108.HKD","SGXZ51526630.SGD","VKTX","LU0256863902.USD","LU2471134879.HKD","LLY","IE00B19Z3581.USD","LU2324357040.USD","SG9999018865.SGD","LU1066053197.SGD","LU0640476718.USD","LU1066051498.USD","LENZ","LU2491050071.SGD","SG9999018857.SGD"],"gpt_icon":1},{"id":"2528671237","title":"BUZZ-Eli Lilly jumps as pill leads to 7.9% weight loss in late-stage trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2528671237","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528671237?lang=en_us&edition=fundamental","pubTime":"2025-04-17 20:53","pubTimestamp":1744894413,"startTime":"0","endTime":"0","summary":"BUZZ-Eli Lilly jumps as pill leads to 7.9% weight loss in late-stage trialUpdates** Shares of drugmaker Eli Lilly LLY.N rise 12.7% to $828.67 premarket** Company says its small molecule oral drug orforglipron led to an average weight loss of 7.9% and lowered blood sugar for overweight patients with type 2 diabetes in a late-stage trial** Shares of Structure Therapeutics GPCR.O, which is also developing a small molecule oral weight loss drug, gain 17.7% before the bell** U.S.-listed shares of Lilly's obesity drug rival Novo Nordisk NOVOb.CO down 6%** Other weight-loss drug developers such as Viking Therapeutics VKTX.O down 5.1% and Amgen AMGN.O down 2.8%** Up to last close, LLY shares down 4.8%, VKTX down 41.2% YTD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nL4N3QV176:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0096364046.USD","LU1868836914.USD","LU0203202063.USD","LU1093756168.USD","LU0889565916.HKD","LU1093756325.SGD","LU2357305700.SGD","LU0417517546.SGD","LU0109394709.USD","IE00B1BXHZ80.USD","LU0882574139.USD","SG9999014906.USD","LU1720051108.HKD","SGXZ99366536.SGD","LU0943347566.SGD","IE00B4R5TH58.HKD","LU0106261372.USD","LU0058720904.USD","BK4533","LU1023059063.AUD","LU1551013425.SGD","LLY","GPCR","LU0122379950.USD","LU2468319806.SGD","LU1988902786.USD","LU0289739699.SGD","LU0256863811.USD","LU1366192091.USD","BK4599","LU1548497426.USD","LU2242646821.SGD","LU0820561909.HKD","SG9999001440.SGD","SGXZ51526630.SGD","LU2491050154.USD","AMGN","SGXZ31699556.SGD","LU2237443622.USD","SG9999014898.SGD","LU0109391861.USD","LU2237438978.USD","IE0009355771.USD","LU2361044865.SGD","LU2360106947.USD","LU2237443978.SGD","LU1057294990.SGD","LU0820561818.USD","VKTX","LU2750360997.AUD"],"gpt_icon":1},{"id":"2528802715","title":"Shares of Obesity Drug Developer Structure Therapeutics up 24.6% Premarket After Eli Lilly's Pill Leads to 7.9% Weight Loss in Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2528802715","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528802715?lang=en_us&edition=fundamental","pubTime":"2025-04-17 19:42","pubTimestamp":1744890170,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QU2P0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","GPCR","BK4599"],"gpt_icon":0},{"id":"2527444107","title":"NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2527444107","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527444107?lang=en_us&edition=fundamental","pubTime":"2025-04-15 22:00","pubTimestamp":1744725600,"startTime":"0","endTime":"0","summary":"Obesity stocks like Novo Nordisk NVO, Eli Lilly LLY, Structure Therapeutics GPCR and Viking Therapeutics VKTX gained 2.1%, 3%, 10.6% and 19.2%, respectively, on Monday after pharma bigwig Pfizer PFE announced that it is discontinuing the development of its GLP-1R weight loss pill, danuglipron.After reviewing all clinical data and considering regulatory feedback, Pfizer concluded that halting the program was the best course of action. This decision reverted Pfizer’s developmental program for an obesity candidate back to the early clinical stages and has significantly delayed its hopes for marketing an obesity drug that would compete with Lilly’s Zepbound and Novo Nordisk’s Wegovy for market share.How PFE’s Obesity Study Setback Benefits VKTX, GPCR, LLY & NVO. Shares of Lilly, Novo Nordisk, Viking Therapeutics and Structure Therapeutics rose as Pfizer's decision to discontinue its obesity pill program removes a ke","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nvo-lly-gpcr-vktx-stocks-140000975.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","LU0106261372.USD","SGXZ81514606.USD","LLY","IE00BLSP4452.SGD","LU0096364046.USD","LU0882574055.USD","LU2361044865.SGD","LU0985481810.HKD","LU0820561909.HKD","LU1883839398.USD","LU2471134952.CNY","IE000M9KFDE8.USD","IE00BJT1NW94.SGD","IE00BZ1G4Q59.USD","LU0456855351.SGD","SG9999011175.SGD","LU1093756325.SGD","VKTX","LU1983299246.USD","LU2237443465.HKD","LU1868837300.USD","BK4532","LU1291159041.SGD","LU1069344957.HKD","LU1712237335.SGD","LU2360106947.USD","SG9999014914.USD","LU2552382058.USD","LU1868836757.USD","LU1917777945.USD","BK4599","LU1551013425.SGD","BK4581","NVO","SGXZ99366536.SGD","LU0058720904.USD","LU0672654240.SGD","LU1127390331.HKD","LU1894683348.USD","PFE","SG9999013999.USD","LU1232071149.USD","GPCR","BK4568","LU0354030438.USD","LU0203202063.USD","IE0002141913.USD","LU0868494617.USD","LU0289739699.SGD"],"gpt_icon":1},{"id":"2527964071","title":"Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill","url":"https://stock-news.laohu8.com/highlight/detail?id=2527964071","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527964071?lang=en_us&edition=fundamental","pubTime":"2025-04-14 22:35","pubTimestamp":1744641325,"startTime":"0","endTime":"0","summary":"Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to disco...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/smaller-obesity-drugmakers-jump-after-pfizer-scraps-weight-loss-pill?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/smaller-obesity-drugmakers-jump-after-pfizer-scraps-weight-loss-pill?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0456855351.SGD","BK4599","LU0225771236.USD","LU0985481810.HKD","SG9999003800.SGD","SG9999013999.USD","VKTX","LU0234572021.USD","BK4139","IE0002270589.USD","SG9999011175.SGD","BK4581","IE000M9KFDE8.USD","LU0170899867.USD","SG9999001176.SGD","BK4568","LU0321505439.SGD","LU0058720904.USD","LU1894683264.USD","LU0225284248.USD","BK4592","LU1894683348.USD","BK4550","IE00BLSP4239.USD","IE00BLSP4452.SGD","LU0306806265.USD","LU0289739699.SGD","IE00BBT3K403.USD","LU1023059063.AUD","BK4585","PFE","LU1066053197.SGD","LU1057294990.SGD","LU0306807586.USD","GPCR","SGXZ57979304.SGD","LU0122379950.USD","LU1883839398.USD","BK4007","IE00B19Z3581.USD","BK4588","BK4534","LU0321505868.SGD","SG9999002232.USD","SG9999001176.USD","LU0868494617.USD","BK4533","LU1066051498.USD","SG9999002224.SGD","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2527621521","title":"Viking, Structure rally after Pfizer halts obesity drug development","url":"https://stock-news.laohu8.com/highlight/detail?id=2527621521","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527621521?lang=en_us&edition=fundamental","pubTime":"2025-04-14 21:50","pubTimestamp":1744638656,"startTime":"0","endTime":"0","summary":"Shares of Viking Therapeutics (VKTX) are up 13% to $25.17 in early trading while Structure Therapeutics (GPCR) is up 7% to 17.02. Published first o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/viking-structure-rally-after-pfizer-halts-obesity-drug-development?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/viking-structure-rally-after-pfizer-halts-obesity-drug-development?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","BK4588","LU0122379950.USD","LU1066053197.SGD","GPCR","IE00BLSP4452.SGD","LU1066051498.USD","BK4568","LU1894683264.USD","LU0985481810.HKD","SGXZ57979304.SGD","BK4581","IE00BBT3K403.USD","LU1057294990.SGD","LU0225284248.USD","SG9999001176.USD","IE0002270589.USD","LU1883839398.USD","LU0225771236.USD","VKTX","LU0868494617.USD","SG9999013999.USD","SG9999002224.SGD","LU0170899867.USD","BK4139","BK4585","LU0234572021.USD","BK4533","LU0321505868.SGD","BK4550","SG9999011175.SGD","LU0306807586.USD","IE00B19Z3B42.SGD","IE00BLSP4239.USD","LU1023059063.AUD","BK4592","LU0058720904.USD","LU0321505439.SGD","SG9999001176.SGD","IE000M9KFDE8.USD","LU0306806265.USD","LU0289739699.SGD","BK4007","BK4599","LU1894683348.USD","SG9999003800.SGD","SG9999002232.USD","LU0456855351.SGD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2527137975","title":"Obesity Drugmakers Shares Rise After Pfizer Ends Development of Weight-Loss Pill Danuglipron","url":"https://stock-news.laohu8.com/highlight/detail?id=2527137975","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527137975?lang=en_us&edition=fundamental","pubTime":"2025-04-14 21:48","pubTimestamp":1744638490,"startTime":"0","endTime":"0","summary":"","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250414:nFWN3QQ01Z:1","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Obesity Drugmakers Shares Rise After Pfizer Ends Development of Weight-Loss Pill Danuglipron","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","VKTX","LU0321505868.SGD","LU0225284248.USD","LU1023059063.AUD","IE000M9KFDE8.USD","LU1066053197.SGD","IE00BLSP4452.SGD","LU0225771236.USD","BK4534","SG9999003800.SGD","IE0002270589.USD","SG9999013999.USD","LU0122379950.USD","BK4581","BK4585","IE00BLSP4239.USD","LU0306807586.USD","LU1894683264.USD","LU0234572021.USD","SG9999002232.USD","LU0058720904.USD","LU0289739699.SGD","SG9999011175.SGD","IE00B19Z3B42.SGD","LU1894683348.USD","BK4599","BK4588","BK4007","GPCR","IE00BBT3K403.USD","BK4568","SGXZ57979304.SGD","SG9999001176.USD","IE00B19Z3581.USD","LLY","BK4592","LU0321505439.SGD","LU1066051498.USD","LU0306806265.USD","SG9999002224.SGD","LU0868494617.USD","LU0985481810.HKD","LU1883839398.USD","SG9999001176.SGD","LU0170899867.USD","NVO","LU1057294990.SGD","LU0456855351.SGD","BK4533"],"gpt_icon":1},{"id":"2522725673","title":"Press Release: Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2522725673","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522725673?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:00","pubTimestamp":1743076800,"startTime":"0","endTime":"0","summary":"Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year. Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for Mast Cell Diseases, Expected to Initiate in 2025. Well-Capitalized with $420.8M Balance Sheet as of YE 2024 to Support Operating Runway into Early 2028. SOUTH SAN FRANCISCO, Calif., March 27, 2025  -- Septerna, Inc. , a biotechnology company pioneering a new era of G protein-coupled receptor  drug discovery, today provided a corporate overview complete with upcoming milestones and reported fourth quarter and full year 2024 financial results.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","03160","BK4099","BK4007","SEPN","BK4604","BK4599","BK4585","TM","BK4555","BK4588"],"gpt_icon":0},{"id":"2522371948","title":"Biotech stocks have been hit by 'DOGE' and other fears. Why they're a great value now.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522371948","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522371948?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:40","pubTimestamp":1743075600,"startTime":"0","endTime":"0","summary":"Investors' deep pessimism is actually bullish, and less regulatory constraint could fuel new drug approval and M&A. Potential personnel cutbacks at the U.S. Food and Drug Administration also seem troubling. But maybe not. The retirement buyout offers for government employees exclude FDA staff who review drug approvals. \"So far, the FDA cuts have been related to medical technology and not in crucial drug regulatory roles,\" Yee said. He added that several companies have recently told him they've noticed no notable changes or delays at the FDA.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1037948541.HKD","BK4548","LU1023059063.AUD","DNLI","INSM","LU1934455863.HKD","BK4534","LU0070302665.USD","LU1037948897.HKD","SG9999014567.USD","US5Y.BOND","LU0306807586.USD","SG9999002232.USD","US7Y.BOND","LU0289739699.SGD","LU1929549753.HKD","FTC","LU1162221912.USD","LU2361044865.SGD","MRK","LU1093756325.SGD","US6M.BOND","BK4588","LU0320765992.SGD","LU0965509101.SGD","BK4007","GPCR","IE00BBT3K403.USD","US12M.BOND","PFE","US2Y.BOND","IE00BN8TJ469.HKD","LU0861579265.USD","BK4139","LU2023250843.SGD","US10Y.BOND","LU0868494617.USD","SG9999001176.SGD","US30Y.BOND","US3Y.BOND","SWTX","LU1989771016.USD","SG9999001440.SGD","NPV","IE00B2B36J28.USD","BK4535","IE0002141913.USD","LU1430594728.SGD","BHVN","LU2089984988.USD"],"gpt_icon":1},{"id":"2519819833","title":"Septerna, Inc. (SEPN): Among Top Insider Purchases Last Month","url":"https://stock-news.laohu8.com/highlight/detail?id=2519819833","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519819833?lang=en_us&edition=fundamental","pubTime":"2025-03-14 23:26","pubTimestamp":1741965998,"startTime":"0","endTime":"0","summary":"We recently published a list of Top 10 Insider Purchases Last Month. In this article, we are going to take a look at where Septerna, Inc.  stands against other top insider purchases last month.How will new tariffs impact the U.S. economy?What’s next on President Trump’s geopolitical agenda?These are some of the concerning questions influencing market conditions.According to J.P. Morgan’s chief global economist, Bruce Kasman, there is about a 40% chance of a U.S. recession and a risk of lasting damage to the country’s reputation as an investment destination, writes Reuters.“Where we stand now is with a heightened concern about the U.S. economy,” Kasman said to reporters in Singapore on Wednesday.Additionally, Goldman Sachs lowered its 2025-end target for the broader market. “The proximate causes of the market decline are the jump in policy uncertainty largely related to tariffs, concerns about the economic growth outlook, and a positioning unwind, especially among hedge funds,” analysts","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/septerna-inc-sepn-among-top-152638628.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1868837300.USD","BK4127","IE00B19Z3581.USD","SEPN","IE00BSNM7G36.USD","LU2471134879.HKD","LU2471134796.USD","LU0096364046.USD","LU2750360997.AUD","LU2237443549.SGD","BK4516","BK4552","LU1668664300.SGD","LU1868836591.USD","LU2237438978.USD","LU0061475181.USD","IE00BFXG1179.USD","BK4550","LU2237443622.USD","IE00B19Z3B42.SGD","BK4599","LU1791807156.HKD","BK4585","LU1868836757.USD","LU1868836914.USD","LU1868837136.USD","LU2237443465.HKD","LU2237443978.SGD","LU2471134523.USD","BK4588","IE0034235188.USD","BK4533","LU2237443382.USD","LU2471134952.CNY","BK4007","IE0004086264.USD","IE0004091025.USD","LU2750360641.GBP","GPCR","IE0002270589.USD","LU0106831901.USD","BK4504","LU2237443895.HKD"],"gpt_icon":0},{"id":"2517613054","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Fate Therapeutics (FATE), Organon (OGN) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517613054","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517613054?lang=en_us&edition=fundamental","pubTime":"2025-03-06 18:30","pubTimestamp":1741257042,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Fate Therapeutics (FATE – Research Report), Organon (OGN – Resear...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-fate-therapeutics-fate-organon-ogn-and-structure-therapeutics-inc-sponsored-adr-gpcr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-fate-therapeutics-fate-organon-ogn-and-structure-therapeutics-inc-sponsored-adr-gpcr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4599","BK4585","GPCR","BK4137","BK4559","BK4588","OGN","FATE","LU2065170008.USD","LU2065171402.SGD","BK4007","BK4139","LU2065171311.SGD","HCSG","LU2065169927.USD"],"gpt_icon":0},{"id":"2517945314","title":"BUZZ-Jefferies looks to Lilly data to reignite interest in obesity stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2517945314","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517945314?lang=en_us&edition=fundamental","pubTime":"2025-03-05 23:21","pubTimestamp":1741188086,"startTime":"0","endTime":"0","summary":"BUZZ-Jefferies looks to Lilly data to reignite interest in obesity stocks** Brokerage Jefferies says investor sentiment on obesity stocks is \"mixed\" at best, but hopes that positive data from Eli Lilly's LLY.N oral obesity drug will bring investors back into this space** LLY shares fell 8% after company's Q3 weight-loss drug sales missed estimates, but have since recovered; its stock is up 19% YTD ** LLY is expected to report late-stage data on its experimental obesity drug, orforglipron, by April** \"We would like to see positive LLY orfo data help drive the obesity comps back up and bring investors back into this space\" - Jefferies ** Outside LLY as the leader, Jefferies says it likes Amgen AMGN.O and Structure Therapeutics GPCR.O, which are both expected to report data on their experimental drugs in H2 ** AMGN up 11.7%, GPCR down 46.6% and LLY up 14.9% in the past 12 months  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nL3N3PO11S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443465.HKD","LU1623119135.USD","LU1093756168.USD","LU1720051017.SGD","BK4139","LU2237443382.USD","LU0203201768.USD","LU0289739699.SGD","LU0672654240.SGD","LU2242646821.SGD","LU1551013342.USD","LU2461242641.AUD","LLY","LU0823416689.USD","LU2324357040.USD","BK4581","LU0203202063.USD","BK4588","LU1023059063.AUD","LU0198837287.USD","LU1712237335.SGD","LU2491050154.USD","LU1868836591.USD","SGXZ99366536.SGD","SG9999001440.SGD","SG9999017495.SGD","AMGN","SG9999015952.SGD","SG9999001176.SGD","LU0456855351.SGD","LU0354030438.USD","SG9999018857.SGD","LU1868836757.USD","LU0097036916.USD","LU0094547139.USD","IE0002141913.USD","GPCR","LU0385154629.USD","LU2468319806.SGD","SG9999014880.SGD","IE00B2B36J28.USD","LU1061106388.HKD","LU1988902786.USD","LU0320765992.SGD","IE00BJJMRZ35.SGD","LU2106854487.HKD","LU1057294990.SGD","LU1720051108.HKD","LU1093756325.SGD","LU0471298694.HKD"],"gpt_icon":1},{"id":"2516634659","title":"AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.","url":"https://stock-news.laohu8.com/highlight/detail?id=2516634659","media":"Blockhead","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516634659?lang=en_us&edition=fundamental","pubTime":"2025-03-03 23:04","pubTimestamp":1741014273,"startTime":"0","endTime":"0","summary":"AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based Gubra A/S.","market":"hk","thumbnail":"https://www.investors.com/wp-content/uploads/2018/06/stock-AbbVie-04-company-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2018/06/stock-AbbVie-04-company-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/abbvie-stock-weight-loss-drug-gubra-licensing-deal/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["BK4599","SG9999015945.SGD","VKTX","LU1244550221.USD","IE00B42XCP33.USD","LU2361044865.SGD","ABBV","BK4139","LU0109391861.USD","LU1035775433.USD","BK4581","SG9999001176.SGD","LU2133065610.SGD","LU0094547139.USD","LU1496350502.SGD","LU1720051108.HKD","LU1974910355.USD","NVO.AU","LU0234570918.USD","LU0820561818.USD","LU1280957306.USD","LU0708994859.HKD","LU1839511570.USD","LU2237443465.HKD","LU0006306889.USD","IE0002141913.USD","LU1244550494.USD","IE00BJJMRZ35.SGD","LU2491050154.USD","LU2023250504.SGD","LU1917777945.USD","LU2106854487.HKD","LU2324357040.USD","GPCR","LU0122379950.USD","IE0009355771.USD","BK4007","SG9999014914.USD","IE00BKVL7J92.USD","LU1934455863.HKD","LU1720051017.SGD","LU1804176565.USD","BK4532","LU0553294199.USD","LU1267930730.SGD","LU0203202063.USD","LU1868836757.USD","LU2237443549.SGD"],"gpt_icon":1},{"id":"2516092633","title":"Morgan Stanley Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2516092633","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516092633?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:08","pubTimestamp":1741007333,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Terence Flynn maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report) today and set a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-keeps-their-buy-rating-on-structure-therapeutics-inc-sponsored-adr-gpcr-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-keeps-their-buy-rating-on-structure-therapeutics-inc-sponsored-adr-gpcr-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GPCR"],"gpt_icon":0},{"id":"2516379506","title":"Structure Therapeutics Is Maintained at Market Outperform by Citizens Capital Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2516379506","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516379506?lang=en_us&edition=fundamental","pubTime":"2025-02-28 23:58","pubTimestamp":1740758280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GPCR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 28, 2025 10:58 ET (15:58 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","GPCR"],"gpt_icon":0},{"id":"2514329134","title":"William Blair Initiates Structure Therapeutics at Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2514329134","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514329134?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:05","pubTimestamp":1740747928,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) has an average rating of buy and mean price target of $81.88, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","GPCR"],"gpt_icon":0},{"id":"2514326997","title":"Structure Therapeutics Initiated at Outperform by William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2514326997","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514326997?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:16","pubTimestamp":1740744960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GPCR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 28, 2025 07:16 ET (12:16 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","LENZ"],"gpt_icon":0},{"id":"2514318237","title":"U.S. RESEARCH ROUNDUP-Autodesk, Coca-Cola, NetApp","url":"https://stock-news.laohu8.com/highlight/detail?id=2514318237","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514318237?lang=en_us&edition=fundamental","pubTime":"2025-02-28 15:07","pubTimestamp":1740726458,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Autodesk, Coca-Cola, NetApp Feb 28 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Autodesk, Coca-","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nL3N3PJ0KS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CCOI","MNST","SJM","LU2506952097.USD","NTAP","BE","NTLA","BIOA","PSBD","CRBP","LU1037948541.HKD","FOLD","ADSK","IE00B1BXHZ80.USD","IE00BFTCPJ56.SGD","RUN","RKT","LU0175139822.USD","JAMF","LU0965509010.AUD","IE00BBT3K403.USD","NUVL","STWD","KO","IE00BJJMRZ35.SGD","RLAY","LU0289960550.SGD","DUOL","LU0012050646.USD","LU1992135472.HKD","IOVA","IE0002141913.USD","LU0823414478.USD","HRL","ALHC","VAC","ORA","TASK","ARRY","GPCR","COGT","CARS","LU0106261372.USD","ALT","TERN","BK4226","ICUI"],"gpt_icon":1}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":78,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GPCR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-27","symbol":"GPCR","fiscalQuarterEnding":"2024/12","expectedEps":-0.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"post","actualEps":-0.22},{"market":"US","date":"2024-11-13","symbol":"GPCR","fiscalQuarterEnding":"2024/09","expectedEps":-0.19,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-0.2}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GPCR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GPCR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3846,"buy":0.6154,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6154,"analysts":13,"updateTime":1740888000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GPCR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GPCR","date":"2025-04-28","current":-11.110452,"percent":0.921642,"low":-50.180001,"twenty":-25.236622,"median":-20.943017,"eighty":-16.425026,"high":-6.622278,"avg":-21.590336,"sd":7.881275,"marketCap":1361319187},"quantilePoints":[{"date":"2023-02-03","current":-25.001825,"twenty":-43.272389,"median":-43.272389,"eighty":-32.310051,"marketCap":951294422},{"date":"2023-02-10","current":-22.116999,"twenty":-35.964163,"median":-23.496907,"eighty":-22.21316,"marketCap":841529681},{"date":"2023-02-17","current":-21.285207,"twenty":-24.521021,"median":-22.645883,"eighty":-21.915061,"marketCap":809880847},{"date":"2023-02-24","current":-23.36709,"twenty":-23.715192,"median":-22.645883,"eighty":-21.847749,"marketCap":889094402},{"date":"2023-03-03","current":-25.530709,"twenty":-24.422936,"median":-22.718004,"eighty":-21.972757,"marketCap":971417957},{"date":"2023-03-10","current":-22.636267,"twenty":-24.85566,"median":-22.790125,"eighty":-22.063149,"marketCap":861287334},{"date":"2023-03-17","current":-22.232392,"twenty":-24.422936,"median":-22.70358,"eighty":-22.09392,"marketCap":845920270},{"date":"2023-03-24","current":-21.876596,"twenty":-23.762311,"median":-22.568955,"eighty":-21.891982,"marketCap":832382619},{"date":"2023-03-31","current":-16.960589,"twenty":-23.565181,"median":-22.314128,"eighty":-21.634271,"marketCap":870434396},{"date":"2023-04-06","current":-17.823234,"twenty":-23.376706,"median":-22.232392,"eighty":-21.285207,"marketCap":914706175},{"date":"2023-04-14","current":-17.473898,"twenty":-23.36709,"median":-22.116999,"eighty":-18.643102,"marketCap":896777933},{"date":"2023-04-21","current":-17.210114,"twenty":-23.194,"median":-22.059302,"eighty":-17.623613,"marketCap":883240282},{"date":"2023-04-28","current":-17.815518,"twenty":-23.078607,"median":-21.876596,"eighty":-17.586227,"marketCap":914310203},{"date":"2023-05-05","current":-17.709107,"twenty":-22.982446,"median":-21.689083,"eighty":-17.623613,"marketCap":908849077},{"date":"2023-05-12","current":-17.00755,"twenty":-22.790125,"median":-21.491953,"eighty":-17.586227,"marketCap":956079400},{"date":"2023-05-19","current":-15.32957,"twenty":-22.780509,"median":-20.818827,"eighty":-17.473898,"marketCap":861751761},{"date":"2023-05-26","current":-19.808636,"twenty":-22.761276,"median":-19.808636,"eighty":-17.466769,"marketCap":1113542462},{"date":"2023-06-02","current":-21.830342,"twenty":-22.668962,"median":-20.674586,"eighty":-17.472472,"marketCap":1227192672},{"date":"2023-06-09","current":-23.110075,"twenty":-22.668962,"median":-21.38858,"eighty":-17.563702,"marketCap":1299132872},{"date":"2023-06-16","current":-21.061141,"twenty":-22.668962,"median":-21.491953,"eighty":-17.586212,"marketCap":1183952020},{"date":"2023-06-23","current":-21.782692,"twenty":-22.640113,"median":-21.568882,"eighty":-17.608538,"marketCap":1224514048},{"date":"2023-06-30","current":-27.561913,"twenty":-22.772816,"median":-21.571672,"eighty":-17.623492,"marketCap":1549392931},{"date":"2023-07-07","current":-24.451072,"twenty":-23.059375,"median":-21.612515,"eighty":-17.625039,"marketCap":1374517018},{"date":"2023-07-14","current":-21.428724,"twenty":-23.103781,"median":-21.707815,"eighty":-17.644282,"marketCap":1204615694},{"date":"2023-07-21","current":-23.069233,"twenty":-23.103781,"median":-21.780436,"eighty":-17.700571,"marketCap":1296836908},{"date":"2023-07-28","current":-23.552536,"twenty":-23.333385,"median":-21.782692,"eighty":-17.727736,"marketCap":1324005814},{"date":"2023-08-04","current":-21.592094,"twenty":-23.51737,"median":-21.782692,"eighty":-17.804907,"marketCap":1213799550},{"date":"2023-08-11","current":-19.978813,"twenty":-23.374783,"median":-21.781564,"eighty":-17.817061,"marketCap":1123108978},{"date":"2023-08-18","current":-16.072919,"twenty":-23.333385,"median":-21.735043,"eighty":-17.644282,"marketCap":1053531639},{"date":"2023-08-25","current":-16.66259,"twenty":-23.197654,"median":-21.646551,"eighty":-17.586168,"marketCap":1092182818},{"date":"2023-09-01","current":-16.458249,"twenty":-23.185384,"median":-21.592094,"eighty":-17.468195,"marketCap":1078788845},{"date":"2023-09-08","current":-16.680105,"twenty":-23.150918,"median":-21.568882,"eighty":-17.319402,"marketCap":1093330873},{"date":"2023-09-15","current":-18.326514,"twenty":-23.110075,"median":-21.460338,"eighty":-17.211393,"marketCap":1201248026},{"date":"2023-09-22","current":-19.937893,"twenty":-23.078607,"median":-21.067948,"eighty":-17.309925,"marketCap":1306869070},{"date":"2023-09-29","current":-21.876218,"twenty":-23.069233,"median":-21.012104,"eighty":-17.319402,"marketCap":1433920470},{"date":"2023-10-06","current":-37.165618,"twenty":-23.194,"median":-21.285207,"eighty":-17.395476,"marketCap":2436094784},{"date":"2023-10-13","current":-44.162453,"twenty":-23.552536,"median":-21.525005,"eighty":-17.459473,"marketCap":2894716299},{"date":"2023-10-20","current":-45.222784,"twenty":-23.852048,"median":-21.571672,"eighty":-17.466769,"marketCap":2964217822},{"date":"2023-10-27","current":-47.275909,"twenty":-23.892891,"median":-21.592094,"eighty":-17.469621,"marketCap":3098794020},{"date":"2023-11-03","current":-48.538851,"twenty":-24.328544,"median":-21.646551,"eighty":-17.490333,"marketCap":3181576088},{"date":"2023-11-10","current":-38.273225,"twenty":-24.864943,"median":-21.735043,"eighty":-17.514986,"marketCap":2508695101},{"date":"2023-11-17","current":-27.570058,"twenty":-25.04304,"median":-21.781564,"eighty":-17.543453,"marketCap":2122673903},{"date":"2023-11-24","current":-32.691508,"twenty":-27.365869,"median":-21.782692,"eighty":-17.586168,"marketCap":2516984612},{"date":"2023-12-01","current":-35.337541,"twenty":-28.3175,"median":-21.830342,"eighty":-17.593664,"marketCap":2720707940},{"date":"2023-12-08","current":-37.983573,"twenty":-33.138225,"median":-21.904522,"eighty":-17.623452,"marketCap":2924431267},{"date":"2023-12-15","current":-37.177707,"twenty":-34.105722,"median":-22.049686,"eighty":-17.625039,"marketCap":2862386033},{"date":"2023-12-22","current":-20.939825,"twenty":-34.105722,"median":-22.001606,"eighty":-17.644282,"marketCap":1612198995},{"date":"2023-12-29","current":-23.446258,"twenty":-34.065552,"median":-22.068918,"eighty":-17.684898,"marketCap":1805174329},{"date":"2024-01-05","current":-26.187472,"twenty":-34.000259,"median":-22.102574,"eighty":-17.702705,"marketCap":2016225834},{"date":"2024-01-12","current":-28.789086,"twenty":-33.67371,"median":-22.232392,"eighty":-17.746366,"marketCap":2216529345},{"date":"2024-01-19","current":-27.710368,"twenty":-33.290514,"median":-22.259189,"eighty":-17.804907,"marketCap":2133476670},{"date":"2024-01-26","current":-26.745867,"twenty":-33.138225,"median":-22.283013,"eighty":-17.817061,"marketCap":2059217807},{"date":"2024-02-02","current":-28.598724,"twenty":-32.691508,"median":-22.44298,"eighty":-17.823234,"marketCap":2201872991},{"date":"2024-02-09","current":-29.823387,"twenty":-32.667396,"median":-22.576119,"eighty":-17.835432,"marketCap":2296162205},{"date":"2024-02-16","current":-28.427399,"twenty":-32.293017,"median":-22.636267,"eighty":-17.890184,"marketCap":2188682272},{"date":"2024-02-23","current":-26.035182,"twenty":-31.181303,"median":-22.647193,"eighty":-17.91403,"marketCap":2004500750},{"date":"2024-03-01","current":-25.743294,"twenty":-31.092467,"median":-22.775115,"eighty":-17.959972,"marketCap":1982027673},{"date":"2024-03-08","current":-22.849791,"twenty":-30.933832,"median":-22.849791,"eighty":-18.031985,"marketCap":1759251085},{"date":"2024-03-15","current":-18.291889,"twenty":-29.823387,"median":-22.775115,"eighty":-18.031985,"marketCap":1639319082},{"date":"2024-03-22","current":-22.815466,"twenty":-29.601298,"median":-22.761276,"eighty":-18.070517,"marketCap":2044722039},{"date":"2024-03-28","current":-22.311113,"twenty":-29.398245,"median":-22.645883,"eighty":-18.070517,"marketCap":1999521939},{"date":"2024-04-05","current":-20.434088,"twenty":-29.301795,"median":-22.601624,"eighty":-18.089549,"marketCap":1831303011},{"date":"2024-04-12","current":-20.928042,"twenty":-29.107626,"median":-22.568955,"eighty":-18.098906,"marketCap":1875571150},{"date":"2024-04-19","current":-18.81184,"twenty":-29.061939,"median":-22.455039,"eighty":-18.224405,"marketCap":1685917123},{"date":"2024-04-26","current":-20.267704,"twenty":-28.863962,"median":-22.311113,"eighty":-18.256547,"marketCap":1816391638},{"date":"2024-05-03","current":-20.281918,"twenty":-28.794162,"median":-22.289169,"eighty":-18.270537,"marketCap":1817665530},{"date":"2024-05-10","current":-20.105056,"twenty":-28.789086,"median":-22.270856,"eighty":-18.288305,"marketCap":1801815151},{"date":"2024-05-17","current":-17.123915,"twenty":-28.636796,"median":-22.232392,"eighty":-18.098906,"marketCap":1672681180},{"date":"2024-05-24","current":-18.288418,"twenty":-28.476893,"median":-22.116999,"eighty":-18.062811,"marketCap":1786430959},{"date":"2024-05-31","current":-16.11295,"twenty":-28.435013,"median":-22.068918,"eighty":-17.902107,"marketCap":1573929112},{"date":"2024-06-07","current":-26.55105,"twenty":-28.381712,"median":-22.102574,"eighty":-17.902107,"marketCap":2593533072},{"date":"2024-06-14","current":-24.646705,"twenty":-28.337752,"median":-22.198735,"eighty":-17.932407,"marketCap":2407514791},{"date":"2024-06-21","current":-22.312809,"twenty":-28.3175,"median":-22.24579,"eighty":-17.974375,"marketCap":2179537500},{"date":"2024-06-28","current":-18.680713,"twenty":-28.3175,"median":-22.24579,"eighty":-18.00318,"marketCap":1824750754},{"date":"2024-07-05","current":-17.874111,"twenty":-28.267548,"median":-22.198735,"eighty":-17.932407,"marketCap":1745961056},{"date":"2024-07-12","current":-20.408464,"twenty":-28.068249,"median":-22.08815,"eighty":-17.932407,"marketCap":1993519219},{"date":"2024-07-15","current":-20.943017,"twenty":-28.006064,"median":-22.078534,"eighty":-17.941595,"marketCap":2045734877},{"date":"2024-08-02","current":-17.387286,"twenty":-27.943879,"median":-22.068918,"eighty":-17.908069,"marketCap":1698407510},{"date":"2024-08-09","current":-16.461364,"twenty":-27.802578,"median":-21.942986,"eighty":-17.823234,"marketCap":1607962532},{"date":"2024-08-16","current":-20.792004,"twenty":-27.780694,"median":-21.876596,"eighty":-17.821691,"marketCap":2088244945},{"date":"2024-08-23","current":-22.295452,"twenty":-27.74971,"median":-21.929398,"eighty":-17.823234,"marketCap":2239243758},{"date":"2024-08-30","current":-21.822777,"twenty":-27.716713,"median":-21.953525,"eighty":-17.863936,"marketCap":2191770646},{"date":"2024-09-06","current":-21.851252,"twenty":-27.691332,"median":-21.926349,"eighty":-17.874111,"marketCap":2194630472},{"date":"2024-09-13","current":-22.944669,"twenty":-27.671026,"median":-21.901472,"eighty":-17.880178,"marketCap":2304447790},{"date":"2024-09-20","current":-22.067657,"twenty":-27.608415,"median":-21.926349,"eighty":-17.902107,"marketCap":2216365150},{"date":"2024-09-27","current":-23.650834,"twenty":-27.565171,"median":-22.001606,"eighty":-17.941595,"marketCap":2375371475},{"date":"2024-10-04","current":-24.083644,"twenty":-27.536769,"median":-22.068918,"eighty":-18.000093,"marketCap":2418840830},{"date":"2024-10-11","current":-22.130301,"twenty":-27.481934,"median":-22.12365,"eighty":-18.029927,"marketCap":2222656767},{"date":"2024-10-18","current":-22.563112,"twenty":-27.163394,"median":-22.116999,"eighty":-18.055104,"marketCap":2266126122},{"date":"2024-10-25","current":-21.333018,"twenty":-26.967956,"median":-22.11226,"eighty":-18.070517,"marketCap":2142581639},{"date":"2024-10-31","current":-21.560813,"twenty":-26.932422,"median":-22.097835,"eighty":-18.080033,"marketCap":2165460247},{"date":"2024-11-08","current":-21.839862,"twenty":-26.875803,"median":-22.107521,"eighty":-18.096607,"marketCap":2193486542},{"date":"2024-11-15","current":-19.500107,"twenty":-26.820843,"median":-22.068288,"eighty":-18.16223,"marketCap":2155736838},{"date":"2024-11-22","current":-15.573182,"twenty":-26.740791,"median":-22.039183,"eighty":-18.047398,"marketCap":1721615252},{"date":"2024-11-29","current":-17.170432,"twenty":-26.702879,"median":-21.932448,"eighty":-17.923218,"marketCap":1898191276},{"date":"2024-12-06","current":-16.181125,"twenty":-26.575564,"median":-21.883856,"eighty":-17.833409,"marketCap":1788823393},{"date":"2024-12-13","current":-16.424567,"twenty":-26.524021,"median":-21.851252,"eighty":-17.817061,"marketCap":1815735909},{"date":"2024-12-20","current":-15.523314,"twenty":-26.386717,"median":-21.835102,"eighty":-17.715324,"marketCap":1716102339},{"date":"2024-12-27","current":-15.30059,"twenty":-26.269962,"median":-21.822777,"eighty":-17.687076,"marketCap":1691480250},{"date":"2025-01-03","current":-14.601342,"twenty":-26.20397,"median":-21.78933,"eighty":-17.625803,"marketCap":1614178343},{"date":"2025-01-10","current":-14.005686,"twenty":-26.17605,"median":-21.782692,"eighty":-17.604018,"marketCap":1548328570},{"date":"2025-01-17","current":-13.974608,"twenty":-26.160821,"median":-21.780436,"eighty":-17.514986,"marketCap":1544892930},{"date":"2025-01-24","current":-14.482211,"twenty":-26.10752,"median":-21.737354,"eighty":-17.469621,"marketCap":1601008389},{"date":"2025-01-31","current":-15.7046,"twenty":-26.035182,"median":-21.700984,"eighty":-17.381485,"marketCap":1736143575},{"date":"2025-02-07","current":-15.549212,"twenty":-26.032644,"median":-21.680405,"eighty":-17.295679,"marketCap":1718965373},{"date":"2025-02-14","current":-12.622728,"twenty":-25.9819,"median":-21.605123,"eighty":-17.234446,"marketCap":1395442576},{"date":"2025-02-21","current":-12.115125,"twenty":-25.903236,"median":-21.581883,"eighty":-17.21037,"marketCap":1339327118},{"date":"2025-02-28","current":-11.819887,"twenty":-25.84482,"median":-21.567582,"eighty":-17.171628,"marketCap":1306688535},{"date":"2025-03-07","current":-11.01217,"twenty":-25.735679,"median":-21.559435,"eighty":-17.124089,"marketCap":1349277189},{"date":"2025-03-14","current":-9.547313,"twenty":-25.689992,"median":-21.491953,"eighty":-17.045645,"marketCap":1169794078},{"date":"2025-03-21","current":-10.235281,"twenty":-25.609403,"median":-21.417887,"eighty":-16.960589,"marketCap":1254088063},{"date":"2025-03-28","current":-9.33203,"twenty":-25.527539,"median":-21.321628,"eighty":-16.93886,"marketCap":1143416369},{"date":"2025-04-04","current":-7.64253,"twenty":-25.480594,"median":-21.202701,"eighty":-16.831205,"marketCap":936408691},{"date":"2025-04-11","current":-7.043483,"twenty":-25.340669,"median":-21.061141,"eighty":-16.666093,"marketCap":863009847},{"date":"2025-04-17","current":-8.672143,"twenty":-25.329214,"median":-21.042579,"eighty":-16.563339,"marketCap":1062562954},{"date":"2025-04-25","current":-11.068331,"twenty":-25.25285,"median":-20.951128,"eighty":-16.426861,"marketCap":1356158331},{"date":"2025-04-28","current":-11.110452,"twenty":-25.236622,"median":-20.943017,"eighty":-16.425026,"marketCap":1361319187}],"updateTime":1745962780445}}}